Cure Today

FDA Approves Guardant360 CDx Diagnostic For Some With Colorectal Cancer

Guardant360 CDx is FDA-approved for identifying BRAF V600E-mutant mCRC patients for targeted therapy with Braftovi, Erbitux, and chemotherapy. The phase 3 BREAKWATER trial showed significant ...
Morningstar

Guardant Health Receives FDA Approval for Guardant360® CDx as Companion Diagnostic for BRAFTOVI® (encorafenib) Combination in Patients with BRAF V600E-Mutant Metastatic ...

First FDA-approved CDx for Guardant360 CDx in colorectal cancer further expands its role in guiding targeted therapy across solid tumors Approval supported by data from Pfizer’s BREAKWATER trial ...
Nasdaq

SERENA-6 Phase III Trial Demonstrates Clinical Value of Guardant360 CDx Test to Detect Emergence of Endocrine Resistance and Inform a Switch in Therapy Before Radiological ...

First pivotal trial to use a circulating tumor DNA (ctDNA)-guided approach to detect and treat emerging resistance in 1st-line therapy ahead of disease progression in breast cancer Trial showed ...
Nasdaq

CORRECTING and REPLACING Guardant Health Launches Guardant360 Tissue, First Tissue Molecular Profiling Test with Comprehensive Multiomic Analysis to Provide a More Complete ...

Powered by Guardant Infinity smart liquid biopsy platform, advanced multiomic test evaluates genomic, epigenomic and RNA-based molecular data First tissue comprehensive genomic profiling test to offer ...